CD4 and pulmonary fibrosis: These findings collaboratively reveal that bortezomib diminishes pulmonary fibrosis by immunoregulatory mechanism, in which suppression of M2 polarization may mediate downregulation of CXCL16 production, thus contributing to impaired accumulation of CXCR6+ CD4 T cells (Fig. 6f).